A5009680639- Bladder and Urothelial Cancer Treatments
- Fibroblast Growth Factor Research
- Epigenetics and DNA Methylation
- Urinary and Genital Oncology Studies
- Cancer Immunotherapy and Biomarkers
- Esophageal Cancer Research and Treatment
- Cancer Research and Treatments
- Ferroptosis and cancer prognosis
- Amino Acid Enzymes and Metabolism
- Cardiovascular Disease and Adiposity
- Urological Disorders and Treatments
- Urinary Tract Infections Management
- Immune Cell Function and Interaction
- Cancer Genomics and Diagnostics
- COVID-19 and healthcare impacts
- Immune cells in cancer
- Cancer, Stress, Anesthesia, and Immune Response
- Immune responses and vaccinations
- Cancer, Hypoxia, and Metabolism
- Peptidase Inhibition and Analysis
- Diet and metabolism studies
- SARS-CoV-2 detection and testing
- COVID-19 Clinical Research Studies
- Tea Polyphenols and Effects
- Dietary Effects on Health
Erasmus MC Cancer Institute
2019-2025
Erasmus MC
2018-2025
Erasmus University Rotterdam
2024
The recommended treatment for patients with high-risk non-muscle-invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) instillations. However, only 50% of benefit from this therapy. If progression to advanced disease occurs, then must undergo a radical cystectomy risks substantial morbidity and poor clinical outcome. Identifying tumors unlikely respond BCG can translate into alternative treatments, such as early cystectomy, targeted...
Bladder cancer (BC) cell lines are indispensable in basic and preclinical research. Currently, an up-to-date comprehensive overview of available BC is not available.To provide resources on the origin, pathological molecular characteristics commonly used human, murine canine lines.A PubMed search was performed for relevant articles published between 1980 2017 according to following MeSH terms: line; line, tumor; urinary bladder neoplasms; carcinoma, transitional cell. The Cellosaurus database...
The recommended treatment for patients with Bacillus Calmette-Guérin (BCG) unresponsive non-muscle invasive bladder cancer (NMIBC) is radical cystectomy (RC). However, many refuse, or are unfit RC. Therefore, alternative bladder-sparing modalities needed BCG-unresponsive NMIBC. In this study we sought to assess the long-term efficacy of hyperthermic intravesical chemotherapy (HIVEC) as in patients.Retrospectively collected data from 56 NMIBC who received ≥5 HIVEC instillations between...
Abstract Purpose Up to 50% of high-risk non-muscle invasive bladder cancer (HR-NMIBC) patients fail Bacillus Calmette-Guérin (BCG) treatment, resulting in a high risk progression and poor clinical outcomes. Biomarkers that predict outcomes after BCG are lacking. The antitumor effects driven by cytotoxic T cell response, which may be controlled immune checkpoint proteins like Programmed Death Ligand 1 (PD-L1). Here, we hypothesized PD-L1 protein expression could serve as biomarker for...
Patients with muscle-invasive bladder cancer (MIBC) who receive radiotherapy curative intent are followed by imaging, cystoscopy, and urine cytology. However, interpretation of cytology cystoscopy is hampered the impact ionizing radiation on cells.
Currently, markers are lacking that can identify patients with high risk nonmuscle invasive bladder cancer who will fail bacillus Calmette-Guérin treatment. Therefore, we evaluated the prognostic value of T1 substaging in primary cancer.Patients received ≥5 induction instillations were included. All tumors centrally reviewed, which included (microinvasion vs extensive invasion lamina propria). stratified into or highest subgroups according to major urology guidelines. Primary end point was...
High-risk non-muscle invasive bladder cancer (HR-NMIBC) patients require long-term surveillance with cystoscopies, cytology and upper tract imaging. Previously, we developed a genomic urine assay for of HR-NMIBC high sensitivity anticipatory value.
Molecular subtypes of muscle-invasive bladder cancer (MIBC) display differential survival and drug sensitivities in clinical trials. To date, they have not been used as a paradigm for phenotypic discovery. This study aimed to discover novel subtype-stratified therapy approaches based on high-content screening (HCS) Transcriptome expression data CCLE BLA-40 cell lines were molecular subtype assignment basal, luminal, mesenchymal-like lines. Two independent HCSs, using focused compound...
Summary The recommended treatment for patients with high-risk non-muscle invasive bladder cancer (HR-NMIBC) is tumor resection followed by adjuvant Bacillus Calmette-Guérin (BCG) instillations. However, only 50% of benefit from this therapy. In case progression to advanced disease, must undergo a radical cystectomy significant morbidity and have poor clinical outcome. Identifying tumors least likely respond BCG can translate into alternative treatments, such as early or novel targeted...
The GARNER study investigated fibroblast growth factor receptor (FGFR) alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette-Guérin (BCG) treatment in high-risk non-muscle invasive bladder cancer (HR-NMIBC). An FGFR predictive response signature (FGFR-PRS) was discovered that identifies patients an activated pathway who could potentially benefit from FGFR-targeted therapy beyond those are ALT (+).
<p>Supplementary Data Tables</p>
<p>Figure S1</p>
<p>Figure S6</p>
<p>Figure S2</p>
<p>Figure S4</p>
<p>Figure S3</p>
<div>AbstractPurpose:<p>The Genomic Analysis of High-Risk Non–Muscle-Invasive Bladder Cancer (GARNER) study investigated FGFR alteration (ALT) frequency and the clinical outcome relationship with Bacillus Calmette–Guérin (BCG) treatment in high-risk non–muscle-invasive bladder cancer (HR-NMIBC). An predictive response signature (FGFR-PRS) was discovered that identifies patients an activated pathway who could potentially benefit from FGFR-targeted therapy beyond those are ALT...